Diverse heterocyclic scaffolds as allosteric inhibitors of AKT

Journal of Medicinal Chemistry

Volumn 55, Issue 3, 2012, Pages 1261-1273

  Kettle, Jason G ^a   Brown, Simon ^a   Crafter, Claire ^a   Davies, Barry R ^a   Dudley, Phillippa ^a   Fairley, Gary ^a   Faulder, Paul ^a   Fillery, Shaun ^a   Greenwood, Hannah ^a   Hawkins, Janet ^a   James, Michael ^a   Johnson, Keith ^a   Lane, Clare D ^a   Pass, Martin ^a   Pink, Jennifer H ^a   Plant, Helen ^a   Cosulich, Sabina C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 PHENYLIMIDAZO[1,2 A]PYRIDIN 2 YL)PHENYL]CYCLOBUTANAMINE; 1 [4 (3 PHENYLPYRAZOLO[1,5 A]PYRIDIN 2 YL)PHENYL]CYCLOBUTANAMINE; 1 [4 (3 PHENYLQUINOLIN 2 YL)PHENYL]CYCLOBUTANAMINE; 1 [4 (3 PHENYLQUINOLIN 2 YL)PHENYL]CYCLOBUTANECARBONITRILE; 1 [4 (3 PHENYLQUINOLIN 2 YL)PHENYL]CYCLOBUTANECARBOXYLIC ACID; 1 [4 (5 AMINO 3 CHLOROPYRAZIN 2 YL)PHENYL]CYCLOBUTYLCARBAMATE; 1 [4 (5 PHENYLIMIDAZO[1,2 A]PYRAZIN 6 YL)PHENYL]CYCLOBUTANAMINE; 1 [4 (7 PHENYLIMIDAZO[1,2 B]PYRIDAZIN 6 YL)PHENYL]CYCLOBUTANAMINE; 2 [4 (1 ISOCYANATOCYCLOBUTYL)PHENYL] 3 PHENYLQUINOLINE; 2 [4 (3 PHENYLQUINOLIN 2 YL)PHENYL]ACETONITRILE; 2 [4 [1 (TERT BUTOXYCARBONYLAMINO)CYCLOBUTYL]PHENYL]PYRAZOLO[1,5 A]PYRIDINE 3 CARBOXYLIC ACID; 6 CHLORO 5 PHENYLPYRIDAZIN 3 AMINE; 6 CHLORO 7 PHENYLIMIDAZO[1,2 B]PYRIDAZINE; BIOLOGICAL MARKER; ETHYL 2 [4 [1 [TERT BUTOXYCARBONYL(ETHOXYCARBONYL)AMINO]CYCLOBUTYL]PHENYL]PYRAZOLO[1,5 A]PYRIDINE 3 CARBOXYLATE; ETHYL 3 [4 [1 [TERT BUTOXYCARBONYL(ETHOXYCARBONYL)AMINO]CYCLOBUTYL]PHENYL]PROPIOLATE; GDC 0068; HETEROCYCLIC COMPOUND; MK 2206; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TERT BUTYL 1 (4 ETHYNYLPHENYL)CYCLOBUTYLCARBAMATE; TERT BUTYL 1 [4 (3 BROMOPYRAZOLO[1,5 A]PYRIDIN 2 YL)PHENYL]CYCLOBUTYLCARBAMATE; TERT BUTYL 1 [4 (3 IODOIMIDAZO[1,2 A]PYRIDIN 2 YL)PHENYL]CYCLOBUTYLCARBAMATE; TERT BUTYL 1 [4 (3 PHENYLIMIDAZO[1,2 A]PYRIDIN 2 YL)PHENYL]CYCLOBUTYLCARBAMATE; TERT BUTYL 1 [4 (3 PHENYLPYRAZOLO[1,5 A]PYRIDIN 2 YL)PHENYL]CYCLOBUTYLCARBAMATE; TERT BUTYL 1 [4 (5 AMINO 3 PHENYLPYRAZIN 2 YL)PHENYL]CYCLOBUTYLCARBAMATE; TERT BUTYL 1 [4 (IMIDAZO[1,2 A]PYRIDIN 2 YL)PHENYL]CYCLOBUTYLCARBAMATE; TERT BUTYL N [1 [4 (2 TRIMETHYLSILYLETHYNYL)PHENYL]CYCLOBUTYL]CARBAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PROTEIN PHOSPHORYLATION; RAT; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ALLOSTERIC REGULATION; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMIDAZOLES; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; PYRAZOLES; PYRIDAZINES; PYRIDINES; QUINAZOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 84856876627     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201394e     Document Type: Article

References (28)

1. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer Nat. Rev. Drug Discovery 2009, 8, 627-644
2. Courtney, K. D.; Ryan, B.; Engelman, J. A. The PI3K pathway as a drug target in human cancer J. Clin. Oncol. 2010, 28, 1075-1083
3. Manning, B. D.; Cantley, L. C. Navigating downstream of AKT Cell 2007, 129, 1261-1274
4. Bozulic, L.; Hemmings, B. A. PIKKing on PKB: Regulation of PKB activity by phosphorylation Curr. Opin Cell Biol. 2009, 21, 256-261
5. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 2005, 307, 1098-1101 (Pubitemid 40262113)
6. Pierce, L. R.; Komander, D.; Alessi, D. R. The nuts and bolts of AGC protein kinases Nat. Rev. Mol. Cell Biol. 2010, 11, 9-22
7. Mattmann, M. E.; Stoops, S. L.; Lindsley, C. W. Inhibition of Akt with small molecules and biologics: Historical perspective and current status of the patent landscape Expert Opin. Ther. Pat. 2011, 21 (9) 1309-1338
8. Meuillet, E. J. Novel inhibitors of AKT: Assessment of a different approach targeting the pleckstrin homology domain Curr. Med. Chem. 2011, 18, 2727-2742
9. Okuzumi, T.; Fiedler, D.; Zhang, C.; Gray, D. C.; Aizenstein, B.; Hoffman, R.; Shokat, K. M. Inhibitor hijacking of Akt activation Nat. Chem. Biol. 2009, 5, 484-493
10. Hirai, H.; Sootome, H.; Nakatsuru, Y.; Miyama, K.; Taguchi, S.; Tsujioka, K.; Ueno, Y.; Hatch, H.; Majumder, P. K.; Pan, B.-S.; Kotani, H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo Mol. Cancer Ther. 2010, 9 (7) 1956-1967
11. Mitchell, I. S.; Blake, J. F.; Xu, R.; Kallan, N. C.; Xiao, D.; Spencer, K. L.; Bencsik, J. R.; Liang, J.; Safina, B.; Zhang, B.; Chabot, C.; Do, S. Preparation of cyclopenta[ d ]pyrimidine derivatives as Akt protein kinase inhibitors. PCT Int. Appl. WO2008006040, 2008.
12. Pal, S. K.; Reckamp, K.; Yu, H.; Figlin, R. A. Akt inhibitors in clinical development for the treatment of cancer Expert Opin. Invest. Drugs 2010, 19 (11) 1355-1366
13. Johnson, P. D.; Leach, A.; Luke, R. W. A.; Matusiak, Z. S.; Morris, J. J. Preparation of pyrrolo[2,3- d ]pyrimidine derivatives as protein kinase B inhibitors. WO2009047563.
14. Li, Y.; Liang, J.; Siu, T; Hu, E.; Rossi, M. A.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Robinson, R. G.; Leander, K.; Huber, H. E.; Mittal, S.; Cosford, N.; Prasit, P. Allosteric inhibitors of Akt1 and Akt2: Discovery of [1,2,4]triazolo[3,4- f ][1,6]naphthyridines with potent and balanced activity Bioorg. Med. Chem. Lett. 2009, 19 (3) 834-836
15. Wu, Z.; Hartnett, J. C.; Neilson, L. A.; Robinson, R. G.; Fu, S.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Kral, A. M.; Huber, H. E.; Hartman, G. D.; Bilodeau, M. T. Development of pyridopyrimidines as potent Akt1/2 inhibitors Bioorg. Med. Chem. Lett. 2008, 18 (4) 1274-1279 (Pubitemid 351226553)
16. Lindsley, C. W.; Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E. Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors Bioorg. Med. Chem. Lett. 2005, 15 (3) 761-764 (Pubitemid 40143162)
17. Wu, W.-I.; Voegtli, W. C.; Sturgis, H. L.; Dizon, F. P.; Vigers, G; Brandhuber, B. J Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition PLoS ONE 2010, 5 (9) e12913
18. Cai, Z.-W.; Zhang, Y.; Borzilleri, R. M.; Qian, L.; Barbosa, S.; Wei, D.; Zheng, X.; Wu, L.; Fan, J.; Shi, Z.; Wautlet, B. S.; Mortillo, S.; Jeyaseelan, R.; Kukral, D. W.; Kamath, A.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Barrish, J. C.; Robl, J. A.; Hunt, J. T.; Lombardo, L. J.; Fargnoli, J.; Bhide, R. S. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5- yloxy)-5-methylpyrrolo[2,1- f ][1,2,4]triazin-6-yloxy)propan-2-yl)2- aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215) J. Med. Chem. 2008, 51 (6) 1976-1980 (Pubitemid 351438880)
19. Hoelder, S.; Zuelch, A.; Baer, T.; Maier, T.; Zimmermann, A.; Beckers, T.; Gekeler, V.; Joshi, H.; Munot, Y.; Bhise, U.; Chavan, S.; Shivatare, S.; Patel, S.; Gore, V. Preparation of fused imidazoles for cancer treatment. PCT Int. Appl. WO2009021990, 2009.
20. Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E.; Lindsley, C. W. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors Bioorg. Med. Chem. Lett. 2005, 15 (4) 905-909 (Pubitemid 40458621)
21. Yu, X.; Wu, J. Synthesis of functionalized isoquinolines via sequential cyclization/cross-coupling reactions J. Comb. Chem. 2009, 11 (5) 895-899
22. Hartnett, J. C.; Barnett, S. F.; Bilodeau, M. T.; Defeo-Jones, D.; Hartman, G. D.; Huber, H. E.; Jones, R. E.; Kral, A. M.; Robinson, R. G.; Wu, Z. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors Bioorg. Med. Chem. Lett. 2008, 18 (6) 2194-2197 (Pubitemid 351380851)
23. Maestro, version 9.2; Schrödinger, LLC: New York, 2011.
24. Glide, version 5.7; Schrödinger, LLC: New York, 2011.
25. Sohlenius-Sternbeck, A.-K.; Afzelius, L.; Prusis, P.; Neelissen, J.; Hoogstraate, J.; Johansson, J.; Floby, E.; Bengtsson, A.; Gissberg, O.; Sternbeck, J.; Petersson, C. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds Xenobiotica 2010, 40, 637-649
26. Ashwell, M. A.; Brassard, C.; Filikov, A.; Hill, J.; Koerner, S.; Lapierre, J.-M.; Liu, Y.; Namdev, N.; Nicewonger, R.; Palma, R.; Tandon, M.; Vensel, D.; Matsuda, A.; Iimura, S.; Yamamoto, Y. Preparation of substituted imidazopyridinyl-aminopyridine compounds as antitumor agents. PCT Int. Appl. WO2011082270, 2011.
27. Bell, M. P.; O'Dowd, C. R.; Rountree, J. S. S.; Trevitt, G. P.; Harrison, T.; McFarland, M. M.. Preparation of furopyrimidine and furopyridine derivatives as AKT/PKB inhibitors. PCT Int. Appl. WO2011055115, 2011.
28. Bell, M. P.; O'Dowd, C. R.; Zhang, L.; Tevitt, G. P.; Harrison, T.; Battacharyya, S.; Rountree, J. S. S.; Burkamp, F.; Price, S.; Macleod, C.; Elliott, R. L.; Smith, P.; Blench, T. J.; Dyke, H. J. Preparation of chromen-4-one, pyrano[2,3- c ]pyridin-4-one, and 7 H -pyrano[2,3- e ]indazol-4-one derivatives as anticancer agents. PCT Int. Appl. WO2011033265, 2011.